Peptibase
Hormonal

Octreotide

Also known as: Sandostatin, Octreotide LAR

FDA Approved
Share:

Popular For

Acromegaly, carcinoid tumors, hormone regulation

Key Facts: Octreotide

Category
Hormonal
FDA Status
FDA Approved
Clinical Status
FDA Approved - Multiple indications
Administration
Subcutaneous or intramuscular depot
Typical Dose
100-500 mcg SC 2-3x daily or LAR monthly
Frequency
2-3x daily (SC) or monthly (LAR)
Evidence Level
FDA Approved
Duration
Long-term / chronic use
Also Known As
Sandostatin, Octreotide LAR

Mechanism of Action

Octreotide binds to somatostatin receptors (primarily SST2 and SST5), inhibiting release of GH, glucagon, insulin, and gut hormones. Reduces GI motility and secretions. Has antitumor effects on neuroendocrine tumors.

Research Summary

FDA approved since 1988 with extensive clinical experience. First-line medical therapy for acromegaly. Effective for symptom control in carcinoid syndrome and VIPomas. Long-acting monthly formulation widely used.

Clinical Status:FDA Approved - Multiple indications
Trial Progress:FDA Approved
Pre
I
II
III
IV
FDA

Dosing Information

FDA Approved·Human clinical trials completed, FDA approved

Typical Dosingⓘ

Community experience

Common Dose

100-500 mcg SC 2-3x daily or LAR monthly

Range

50-1500 mcg daily (SC)

Frequency

2-3x daily (SC) or monthly (LAR)

Somatostatin analog. Multiple indications including acromegaly and carcinoid tumors.

Research Dosingⓘ

Scientific studies

FDA-approved dosing

Doses from Studies

50-200 mcg SC 3x daily (immediate)

FDA Approved Labeling - Prescribed dose ↗

Duration

Long-term / chronic use

Administration

Subcutaneous or intramuscular depot

Timing & Administration

Best Time to Take

Morning or as directed

Follow recommended protocol

Food Recommendation

With or without food

Why This Timing?

Timing may vary based on individual response and goals. Consistency is generally more important than specific timing.

Possible Side Effects

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

  • ●Nausea
  • ●Diarrhea
  • ●Abdominal pain
  • ●Gallstones (52-63% long-term)
  • ●Bradycardia
  • ●Hyperglycemia or hypoglycemia
  • ●Hypothyroidism
  • ●Pancreatitis
  • ●FDA approved (Sandostatin)

References

Related Peptides

Peptides commonly compared with Octreotide or used in similar applications.

Insulin

FDA

The essential peptide hormone for glucose metabolism. Multiple formulations from rapid to long-acting available for diabetes management.

Hormonal

Oxytocin

FDA

A naturally occurring peptide hormone crucial for social bonding, childbirth, and lactation. Being studied for autism, anxiety, and social disorders.

Hormonal

Gonadorelin

FDA

A synthetic version of gonadotropin-releasing hormone. Used diagnostically and therapeutically for various reproductive and hormonal conditions.

Hormonal

Leuprolide

FDA

A GnRH agonist that suppresses testosterone and estrogen production. FDA approved for prostate cancer, endometriosis, uterine fibroids, and precocious puberty.

Hormonal

Desmopressin

FDA

A synthetic analog of vasopressin (ADH) used for diabetes insipidus, bedwetting, and bleeding disorders. Does not cause vasoconstriction like natural vasopressin.

Hormonal

Lanreotide

FDA

A long-acting somatostatin analog similar to octreotide. FDA approved for acromegaly and gastroenteropancreatic neuroendocrine tumors.

Hormonal
How to Use OctreotideOctreotide AlternativesCompare with SimilarBrowse All Peptides

Looking for a trusted vendor?

Pro members get access to verified vendors with quality standards & exclusive discount codes.

View Verified Vendors
PRO

Want updates on Octreotide research?

Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.

Back to all peptides